|Bid||169.700 x 0|
|Ask||169.800 x 0|
|Day's Range||167.600 - 191.000|
|52 Week Range||29.300 - 285.800|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CanSino Biologics, a Chinese vaccine company, announced on Friday that it saw strong, positive results from its phase one trials of a coronavirus vaccine, which it tested on 108 volunteers. Yahoo Finance’s Anjalee Khemlani joins The Final Round to break down the latest news about the coronavirus.
President Donald Trump dismissed the idea of a new series of lockdowns should the world’s largest economy experience a second wave of coronavirus infections, which continue to level off as parts of the country reopen.
CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine
CanSino Biologics Inc.'s (HKG:6185): CanSino Biologics Inc. focuses on developing, manufacturing, and commercializing...